This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada’s achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada’s prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high...
Pharmaceutical Pricing and Reimbursement Policies in Canada
Working paper
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
Working paper21 May 202638 Pages
-
10 April 202641 Pages
-
Working paper
Balancing resilience and sustainability in challenging times
31 March 202634 Pages -
Working paper
Lessons for Slovenia
22 January 202672 Pages -
Working paper16 January 202699 Pages
-
Working paper
An analysis of emergency department visits and hospitalisation data from 16 countries
17 December 202555 Pages -
Working paper
New indicators for benchmarking performance
10 December 202572 Pages
Related publications
-
Working paper
Insights from job vacancy data
28 May 202656 Pages -
15 April 2026 -
Report
Implementing the Convention and Related Legal Instruments
31 March 202654 Pages